Strategic collaboration with SGSC – Hardman Research Note

Cizzle Biotechnology (Cizzle), focused on cancer diagnostics, was spun out of the University of York to exploit the biomarker, variant CIZ1b, for early detection of different forms of lung cancer. There is high medical need for a simple blood test, to be used alongside a positive chest scan, that allows early detection of lung cancer. This should result in a significant reduction in the number of false positives, reduce the number of scans and improve patient outcomes. As part of its portfolio expansion and to increase the number of income streams, Cizzle has signed a commercial and royalty deal with respect to a clinical asset, known as AZD1656.

Click here to read the full article.